GlassScriptPhysician profile
Wendell R Malalis
NPI 1962692418
$2,360.58
in general payments reported to CMS, 2019-2025
18 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $121 · 2021: $460 · 2022: $238 · 2023: $192 · 2024: $448 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.70 |
| Education | $290.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.11 | 2019-2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $288.52 | 2019-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $179.17 | 2022-2025 | Mounjaro |
| Boston Scientific Corporation | $170.01 | 2025 | General - Pain Management |
| Beta Bionics, INC. | $162.47 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $160.21 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $144.84 | 2023-2024 | Gvoke Hypopen |
| Medtronic, INC. | $125.35 | 2021-2023 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $120.11 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $93.79 | 2019 | |
| Medtronic Minimed, INC. | $79.57 | 2019 | |
| Ascensia Diabetes Care US INC. | $40.94 | 2024 | |
| Horizon Therapeutics Plc | $40.33 | 2019 | |
| Globus Medical, INC. | $28.04 | 2025 | Vyrsa V1 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.53 | 2022 | |
| Tandem Diabetes Care, INC. | $23.29 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $20.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Malalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.